The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis, a condition commonly seen in people with multiple sclerosis (MS). Optic neuritis, marked by inflammation of the optic nerve that carries signals between the eyes and the brain, can lead to lasting vision problems. While also associated with […]
The post EMA grants PRIME status to new optic neuritis therapy privosegtor appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com